A Phase 1 interventional study of Lorlatinib in Renal Impairment, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 19th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2018, is one of 23 in phase 1, and was the 23rd registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18–80 · Healthy volunteers
Pfizer · Sites in United States
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 1 · Phase 3 4 · Phase 4 8
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 30 across the 36 interventional studies, 59 across the 1 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Renal Insufficiency by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07315360PfizerA Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function | 2027-03-13 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Renal Insufficiency by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment.
This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment. Each subject will receive a single oral dose of lorlatinib administered in the fasted state. Subjects with mild, moderate, and severe renal impairment will be enrolled and normal healthy subjects will be enrolled as matched controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mild renal impairment
Drug: Lorlatinib
Moderate renal impairment
Drug: Lorlatinib
Severe renal impairment
Drug: Lorlatinib
Normal renal function
Drug: Lorlatinib
Lorlatinib single oral dose
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib
AUCinf was calculated by AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration; Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Maximum Observed Plasma Concentration (Cmax) of Lorlatinib
Cmax was observed directly from data.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event did not need to have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Number of participants with both all-causality and treatment-related TEAEs are presented below.
Time frame: Baseline up to 28 days after last dose of study treatment (approximately 29 days)
Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities
The hematology, chemistry and urinalysis tests were included in the laboratory examination. Hematology evaluation included hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte mean corpuscular volume, erythrocyte mean corpuscular hemoglobin concentration and erythrocyte mean corpuscular hemoglobin. Chemistry evaluation included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein, lipase and amylase. Urinalysis evaluation included decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy, ketones, nitrite, leukocyte esterase, urobilinogen, urine bilirubin and bacteria. The lab abnormalities were reported in accordance with the sponsor reporting standards.
Time frame: Screening, Day -1, Day 2 and Day 6
Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria
Vital signs evaluations included supine diastolic blood pressure (DBP), and supine systolic blood pressure (SBP) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. Number of participants with vital signs data meeting the categorical summarization criteria is presented. The pre-specified criteria of vital signs data were categorized as follows: SBP (minimum) \<90 mmHg, maximum of decrease and increase from baseline for SBP \>=30 mmHg; DBP (minimum) \<50 mmHg, maximum of decrease and increase from baseline for DBP\>=20 mmHg.
Time frame: Baseline up to 28 days after last dose of study treatment (approximately 29 days)
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Summarization Criteria
ECG evaluation included: PR interval, time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval), and QT interval corrected for heart rate using Fridericia's formula (QTcF interval). The pre-specified criteria of ESG data were categorized as below.
Time frame: Screening, Day -1, 0 hours (pre-dose), 1 hour, 2 hours, 4 hours, 24 hours and 120 hours postdose.
Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib
AUClast was calculated by linear/Log trapezoidal method.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Time for Cmax (Tmax) of Lorlatinib
Tmax was observed directly from data as time of first occurrence.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Terminal Elimination Plasma Half-life (t½) of Lorlatinib
t1/2 was calculated by ln(2)/kel.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Apparent Clearance After Oral Dose (CL/F) of Lorlatinib
CL/F was calculated by Dose/AUCinf.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Apparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib
Vz/F was calculated by Dose/(AUCinf\*kel). kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
Renal Clearance (CLR) of Lorlatinib
CLR was calculated by Ae/AUClast. Ae was cumulative amount of drug recovered unchanged in urine, which was calculated by sum of (urine concentration × sample volume) for each collection interval from 0 to time 120 hours postdose. Sample volume = (urine weight in g/1.020), where 1.020 g/mL is the approximate specific gravity of urine.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours postdose
The mild renal impairment participants were recruited first. After lorlatinib was tolerated in at least 3 mild impairment participants, moderate impairment participants were enrolled. After dosing of 3 moderate impairment participants for at least 1 week, the remaining moderate impairment participants and the severe impairment participants were enrolled. The enrollment of normal renal function participants began after all renal impairment participants completed the PK collection.
| Milestone | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 5 |
| Completed | 8 | 8 | 8 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
AUCinf was calculated by AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration; Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| ng*hr/mL | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Lorlatinib | 8329 ± 33 | 8683 ± 29 | 9890 ± 27 | 11760 ± 37 |
Cmax was observed directly from data.
| ng/mL | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Lorlatinib | 546.8 ± 48 | 549.7 ± 52 | 485.9 ± 24 | 504.8 ± 50 |
An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event did not need to have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Number of participants with both all-causality and treatment-related TEAEs are presented below.
| Participants | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| All-causality AEs | 5 | 2 | 4 | 1 |
| All-causality SAEs | 0 | 0 | 0 | 0 |
| Treatment-related AEs | 3 | 2 | 1 | 1 |
| Treatment-related SAEs | 0 | 0 | 0 | 0 |
The hematology, chemistry and urinalysis tests were included in the laboratory examination. Hematology evaluation included hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte mean corpuscular volume, erythrocyte mean corpuscular hemoglobin concentration and erythrocyte mean corpuscular hemoglobin. Chemistry evaluation included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein, lipase and amylase. Urinalysis evaluation included decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy, ketones, nitrite, leukocyte esterase, urobilinogen, urine bilirubin and bacteria. The lab abnormalities were reported in accordance with the sponsor reporting standards.
| Participants | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormalities | 4 | 2 | 8 | 5 |
Vital signs evaluations included supine diastolic blood pressure (DBP), and supine systolic blood pressure (SBP) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. Number of participants with vital signs data meeting the categorical summarization criteria is presented. The pre-specified criteria of vital signs data were categorized as follows: SBP (minimum) \<90 mmHg, maximum of decrease and increase from baseline for SBP \>=30 mmHg; DBP (minimum) \<50 mmHg, maximum of decrease and increase from baseline for DBP\>=20 mmHg.
| Participants | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Supine SBP < 90 mmHg | 0 | 1 | 0 | 0 |
| Supine SBP ≥ 30 mmHg increase | 0 | 0 | 2 | 1 |
| Supine SBP ≥ 30 mmHg decrease | 1 | 1 | 0 | 0 |
| Supine DBP < 50 mmHg | 0 | 1 | 0 | 0 |
| Supine DBP ≥ 20 mmHg increase | 0 | 0 | 1 | 1 |
| Supine DBP ≥ 20 mmHg decrease | 0 | 1 | 0 | 0 |
ECG evaluation included: PR interval, time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval), and QT interval corrected for heart rate using Fridericia's formula (QTcF interval). The pre-specified criteria of ESG data were categorized as below.
| Participants | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| PR interval ≥ 200 to <220 msec | 0 | 0 | 0 | 1 |
| PR interval ≥ 200 to <240 msec | 0 | 0 | 0 | 0 |
| PR interval ≥ 240 to <260 msec | 0 | 0 | 0 | 0 |
| PR interval ≥ 260msec | 0 | 0 | 0 | 0 |
| QRS interval >120 msec | 0 | 0 | 0 | 0 |
| QT interval ≥ 500 msec | 0 | 0 | 0 | 0 |
| QTcF interval ≥ 450 to <480 msec | 0 | 0 | 0 | 0 |
| QTcF interval ≥ 480 msec | 0 | 0 | 0 | 0 |
| PR interval change from baseline ≥ 40 to <60 msec | 0 | 0 | 1 | 0 |
| PR interval change from baseline ≥ 60 to <80 msec | 0 | 0 | 0 | 0 |
| PR interval change from baseline ≥ 80 msec | 0 | 0 | 0 | 0 |
| PR interval percent change from baseline > 25% | 0 | 0 | 1 | 0 |
| QRS interval percent change from baseline ≥ 50% | 0 | 0 | 0 | 0 |
| QTcF interval change from baseline ≥ 30 to <60 msec | 0 | 0 | 0 | 0 |
| QTcF interval change from baseline ≥ 60 msec | 0 | 0 | 0 | 0 |
AUClast was calculated by linear/Log trapezoidal method.
| ng*hr/mL | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Lorlatinib | 8015 ± 32 | 8307 ± 28 | 8867 ± 24 | 10310 ± 36 |
Tmax was observed directly from data as time of first occurrence.
| hours | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Time for Cmax (Tmax) of Lorlatinib | 1.50 (1.00 to 4.00) | 1.00 (1.00 to 1.50) | 1.25 (1.00 to 4.00) | 1.00 (1.00 to 1.50) |
t1/2 was calculated by ln(2)/kel.
| hours | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Terminal Elimination Plasma Half-life (t½) of Lorlatinib | 25.64 ± 4.7500 | 28.08 ± 3.5156 | 39.40 ± 7.1019 | 41.66 ± 7.6081 |
CL/F was calculated by Dose/AUCinf.
| L/hr | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Apparent Clearance After Oral Dose (CL/F) of Lorlatinib | 12.02 ± 33 | 11.51 ± 29 | 10.11 ± 27 | 8.51 ± 37 |
Vz/F was calculated by Dose/(AUCinf\*kel). kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| L | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Apparent Volume of Distribution Following Oral Dose (Vz/F) of Lorlatinib | 436.9 ± 24 | 462.9 ± 27 | 566.2 ± 21 | 503.8 ± 36 |
CLR was calculated by Ae/AUClast. Ae was cumulative amount of drug recovered unchanged in urine, which was calculated by sum of (urine concentration × sample volume) for each collection interval from 0 to time 120 hours postdose. Sample volume = (urine weight in g/1.020), where 1.020 g/mL is the approximate specific gravity of urine.
| L/hr | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Renal Clearance (CLR) of Lorlatinib | 0.1095 ± 42 | 0.1382 ± 50 | 0.08199 ± 55 | 0.06872 ± 45 |
Collected over Baseline up to 28 days after last dose of study treatment (approximately 29 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Function | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Mild Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Moderate Impairment | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Severe Impairment | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment |
|---|---|---|---|---|
| Blood pressure increasedInvestigations | 0/8 | 1/8 | 0/8 | 1/5 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/8 | 0/8 | 0/8 | 1/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/8 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/8 | 1/8 | 0/5 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/8 | 1/8 | 0/8 | 0/5 |
| DizzinessNervous system disorders | 1/8 | 0/8 | 1/8 | 0/5 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 1/8 | 0/5 |
| Vessel puncture site painGeneral disorders | 0/8 | 1/8 | 0/8 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 1/8 | 0/8 | 1/8 | 0/5 |
| Skin abrasionInjury, poisoning and procedural complications | 0/8 | 0/8 | 1/8 | 0/5 |
Baseline analysis population included all participants who were randomized.
| Age, Continuous(Years) | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment | Total |
|---|---|---|---|---|---|
| Mean | 56.6 ± 3.66 | 59.0 ± 7.27 | 63.1 ± 4.88 | 60.4 ± 11.08 | 59.7 ± 6.81 |
| Sex: Female, Male(Participants) | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 5 | 1 | 12 |
| Male | 5 | 5 | 3 | 4 | 17 |
| Race/Ethnicity, Customized(Participants) | Normal Function | Mild Impairment | Moderate Impairment | Severe Impairment | Total |
|---|---|---|---|---|---|
| white | 5 | 7 | 8 | 3 | 23 |
| Black or African American | 3 | 0 | 0 | 2 | 5 |
| Asian | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Aug 2018 to primary completion in Feb 2020, 17 months.
Results were first posted in Feb 2021, 1 year after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib